Podrobný výpis o publikaci

SZTURZ, Petr, Pol SPECENIER, Carl VAN LAER, Danielle VAN DEN WEYNGAERT, Bob CORTHOUTS, Laurens CARP, Eric VAN MARCK, Olivier VANDERVEKEN a Jan B. VERMORKEN. Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab. European Archives of Oto-Rhino-Laryngology and Head & Neck. NEW YORK: SPRINGER, 2016, roč. 273, č. 6, s. 1629-1636. ISSN 0937-4477. Dostupné z: https://dx.doi.org/10.1007/s00405-015-3673-y.

Další formáty: BibTeX LaTeX RIS

Základní údaje
Originální název	Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab
Autoři	SZTURZ, Petr (203 Česká republika, garant, domácí), Pol SPECENIER (56 Belgie), Carl VAN LAER (56 Belgie), Danielle VAN DEN WEYNGAERT (56 Belgie), Bob CORTHOUTS (56 Belgie), Laurens CARP (56 Belgie), Eric VAN MARCK (56 Belgie), Olivier VANDERVEKEN (56 Belgie) a Jan B. VERMORKEN (56 Belgie).
Vydání	European Archives of Oto-Rhino-Laryngology and Head & Neck, NEW YORK, SPRINGER, 2016, 0937-4477.

Další údaje
Originální jazyk	angličtina
Typ výsledku	Článek v odborném periodiku
Obor	30200 3.2 Clinical medicine
Stát vydavatele	Spojené státy
Utajení	není předmětem státního či obchodního tajemství
Impakt faktor	Impact factor: 1.660
Kód RIV	RIV/00216224:14110/16:00090827
Organizační jednotka	Lékařská fakulta
Doi	http://dx.doi.org/10.1007/s00405-015-3673-y
UT WoS	000375607700038
Klíčová slova anglicky	Tonsil cancer; Positron emission tomography; Taxanes; Targeted therapy; Epidermal growth factor receptor inhibitor
Štítky	EL OK
Příznaky	Mezinárodní význam, Recenzováno
Změnil	Změnila: Soňa Böhmová, učo 232884. Změněno: 15. 9. 2016 15:20.

Anotace
In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months. In 2005, a male patient, born in 1944, with a second local recurrence of human papillomavirus negative tonsil cancer was enrolled in the EXTREME trial, and randomized to platinum/5-fluorouracil/cetuximab arm resulting in partial remission with progression-free survival of 12 months. The second-line systemic therapy comprised 5 cycles of 3-weekly docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab. As confirmed on imaging and repeated biopsies, complete response was achieved with disease-free survival of 8 years and follow-up period of 12 years. Severe acute toxicities during the taxane-based chemotherapy plus cetuximab included grade 4 anorexia and grade 3 febrile neutropenia. Poor tumor differentiation, no weight loss, oropharyngeal location, white race, and particularly the induced complete response were most likely the key favorable prognostic factors in the reported patient. The possibility of a synergistic interaction between taxanes and cetuximab should be further explored.

Anotace

In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months. In 2005, a male patient, born in 1944, with a second local recurrence of human papillomavirus negative tonsil cancer was enrolled in the EXTREME trial, and randomized to platinum/5-fluorouracil/cetuximab arm resulting in partial remission with progression-free survival of 12 months. The second-line systemic therapy comprised 5 cycles of 3-weekly docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab. As confirmed on imaging and repeated biopsies, complete response was achieved with disease-free survival of 8 years and follow-up period of 12 years. Severe acute toxicities during the taxane-based chemotherapy plus cetuximab included grade 4 anorexia and grade 3 febrile neutropenia. Poor tumor differentiation, no weight loss, oropharyngeal location, white race, and particularly the induced complete response were most likely the key favorable prognostic factors in the reported patient. The possibility of a synergistic interaction between taxanes and cetuximab should be further explored.